Senores Pharmaceuticals Ltd Financials
Company Logo

Senores Pharmaceuticals Ltd Financial Statement

Senores Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Dec 2024
Revenue16.78
Operating Expense12.01
Net Profit1.07
Net Profit Margin6.38
Earning Per Share0.32
EBIDTA4.80
Effective Tax Rate5.87

Senores Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual34.01
Operating Expenses Annual34.07
Operating Profit Annual6.79
Interest Annual2.71
Depreciation1.48
Net Profit Annual0.81
Tax Annual1.22

Senores Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.09
Cash Flow from Operations-62.82
Cash Flow from Investing-13.51
Cash Flow from Financing86.68
Cash Flow at the End10.44

Senores Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)19.94
PBIT Margin (%)13.94
PBT Margin (%)8.79
Net PROFIT Margin (%)2.38
Return On Networth / Equity (%)0.78
Return On Networth /Employed (%)2.56
Return On Assets (%)0.43
Total Debt / Equity (X)0.76
Asset Turnover Ratio (%)0.18

Senores Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual27.68
Total Current Assets Annual39.96
Non Current Assets Annual245.90
Total Shareholders Funds Annual168.12
Total Assets Annual285.86

Senores Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

3.73

Reported

5.04

Surprise

35.12%

Mar 2024

EPS beaten by 35.12%

Dec 2023

EPS beaten by 0.00%

FAQS on Senores Pharmaceuticals Ltd Financials

As of Mar 12, 2025, Senores Pharmaceuticals Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
No, Senores Pharmaceuticals Ltd is not debt-free with a debt-to-equity ratio of 0.60.
In FY 2024 , Senores Pharmaceuticals Ltd recorded a total revenue of approximately 34.01 Cr marking a significant milestone in the company's financial performance.
Senores Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.4% annually, respectively..
Senores Pharmaceuticals Ltd's current PE ratio is undefined.
Senores Pharmaceuticals Ltd's ROCE averaged 2.9% from the FY ending March 2022 to 2024, with a median of 2.9%. It peaked at 4.0% in March 2023, reflecting strong capital efficiency over the period..
Senores Pharmaceuticals Ltd's latest EBIT is Rs. 4.74 Cr, surpassing the average EBIT of Rs. 3.40 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions